NAC Supplementation Shows Promise in Preventing Preterm Birth Risks

A new study has found that antenatal N-acetylcysteine (NAC) supplementation could help prevent preterm birth and reduce complications for both mother and baby. Researchers led by Küster et al. discovered that the treatment lowered maternal infections and improved neonatal outcomes without harming fetal development. The findings suggest NAC may become a key intervention for high-risk pregnancies. The trial focused on pregnant women at risk of preterm birth. Those given NAC showed fewer acute neonatal complications, including infections and inflammatory issues. Importantly, the supplement did not shorten gestation periods or interfere with fetal growth.

NAC works by increasing glutathione levels and adjusting NF-κB pathways, which help control inflammation. The study also stressed that early identification of high-risk cases is essential for maximising the treatment’s benefits. Researchers noted that combining biochemical tests with clinical outcomes could improve how pregnancy therapies are evaluated. While the results are promising, they call for larger, multi-centre trials to confirm the effects across different populations. The success of NAC in preventing preterm birth has sparked interest in its potential for other obstetric conditions. If further studies support these findings, the supplement might reduce long-term disabilities and healthcare costs linked to preterm births.

The study presents strong evidence for NAC as a safe and effective option for women facing preterm labour. By lowering complications and supporting maternal health, it could change how high-risk pregnancies are managed. However, broader trials are still needed before widespread adoption.